Immunitas therapeutics

Immunitas therapeuticsMonoclonal Antibodies Clinical Trial Experiences Momentum [ http://prnewswire.com ] The drug is currently in Phase III testing for the treatment of patients with ...Monoclonal Antibodies Clinical Trial Experiences Momentum [ http://prnewswire.com ] The drug is currently in Phase III testing for the treatment of patients with ...WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated...Feb 17, 2021 · WALTHAM, Mass.-- ( BUSINESS WIRE )--Immunitas Therapeutics (“Immunitas”), a single cell genomics-based drug discovery company, today announced the publication of Inhibitory CD161 Receptor ... "Neil Lerner joined Compass in 2020 as a finance leader with over 20 years of accounting, finance and business experience, including SEC reporting, system implementations, budgeting and forecasting, Sarbanes Oxley (SOX), and cost accounting.\nPrior to joining Compass, Neil led the accounting and finance function of …Monoclonal Antibodies Clinical Trial Experiences Momentum [ http://prnewswire.com ] The drug is currently in Phase III testing for the treatment of patients with ...Jnana Therapeutics is developing medicines that go after hard-to-hit drug targets. With its $50 million Series B round of funding, the company unveiled a lead program in phenylketonuria (PKU), a...🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB WALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B...AUSTIN, Texas, Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Aug 18, 2021 · WALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B... Waltham, Mass., August 18, 2021 – Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark F...Immunitas Therapeutics | 5,521 followers on LinkedIn. The Human Approach to Oncology | Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel …The CEO of Immunitas Therapeutics stepped into the role earlier this month after two years as the startup’s chief business officer. expand Amanda Wagner is the CEO of Immunitas Therapeutics.WALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment...2 days ago · LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline... RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBNov 11, 2022 · WALTHAM, Mass., Nov. 11, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel,... Nov 21, 2019 · Immunitas Therapeutics (“Immunitas”), a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Seri Immunitas Therapeutics Launches with $39... 2 days ago · LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline... Immunitas Therapeutics Experience Director, Head of Antibody Discovery Immunitas Therapeutics May 2022 - Present1 year 1 month Waltham, Massachusetts, United States Compass Therapeutics Inc.... WALTHAM, Mass., Oct. 5, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and …Nov 25, 2021 · The CEO of Immunitas Therapeutics stepped into the role earlier this month after two years as the startup’s chief business officer. Amanda Wagner is the CEO of Immunitas Therapeutics. Courtesy... Nov 30, 2022 · AUSTIN, Texas, Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as... Immunitas Therapeutics (“Immunitas”), a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Seri Immunitas Therapeutics Launches with $39...WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated... holidu
IntersenseWALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated …Basel, Switzerland, 15 April 2021 – Lonza and Immunitas Therapeutics today announced an agreement to advance the manufacturing process for the company's lead drug candidate, IMT-009, using a customized, accelerated version of Lonza's Ibex ® Design program.A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until July 31, 2020 was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene ... top oriental massage
Nextworld evergreen c.h. mueller boon health BPDCN is a unique acute leukaemia that often presents with malignant cells isolated to the skin 13, 14 (Fig. 1a ). Despite this localized presentation, most patients ultimately develop systemic ...10 hours ago · A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until July 31, 2020 was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene ... Immunitas Therapeutics About Ph.D. scientist with expertise in immuno-oncology biomarker discovery, translational cancer models, tumor immune profiling, and T cell and macrophage biology....
Immunitas therapeuticsWALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the first patient has been dosed in a Phase 1/2a clinical trial evaluating use of novel cancer ...Monoclonal Antibodies Clinical Trial Experiences Momentum [ http://prnewswire.com ] The drug is currently in Phase III testing for the treatment of patients with ...Immunitas Therapeutics | 5,747 followers on LinkedIn. The Human Approach to Oncology | Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas Therapeutics 3 years 8 months Chief Executive Officer Nov 2021 - Present1 year 7 months Waltham, MA Fast, collaborative, inclusive. Click the company logo for more info. Chief Business... 2 days ago · The monoclonal antibodies pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. LAS VEGAS ... Aug 22, 2021 · Immunitas adds $58M for CD161-targeting cancer drug. Immunitas Therapeutics emerged in 2019 with technology that enables the company to analyze single cells to identify and validate new drug targets. cambria solutions 1301 smith rd plainfield in 46168
Eg meatA.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until July 31, 2020 was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene ...WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the first patient has been dosed in a Phase 1/2a clinical trial evaluating use of novel cancer imm...Jobs. Number of Current Jobs 1. Number of Past Jobs 2. Lynette Herscha is the Chief Operating Officer at Immunitas Therapeutics. Additionally, Lynette Herscha has had 2 past jobs including Chief Legal Officer at Senda Biosciences. Immunitas Therapeutics Chief Operating Officer Jul 2022. Organization Name.RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB osaro
Sherwood valve mavq RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBWALTHAM, Mass., Sept. 21, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for...2 days ago · LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline... Jun 7, 2023 · (617) 500-8099 Company Compass Therapeutics Neil Lerner Current Workplace Neil Lerner has been working as a Vice President, Finance at Compass Therapeutics for 3 years. Compass Therapeutics is part of the Research & Development industry, and located in Massachusetts, United States. Compass Therapeutics Location WALTHAM, Mass.-- ( BUSINESS WIRE )--Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immuno-oncology therapies for people living with cancer, today announced that...CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Immunitas Therapeutics (“Immunitas”), an innovative single cell genomics discovery platform company focused on developing breakthrough immuno-oncology therapies, today announced it has appointed Jeffrey M. Goldberg as Chief Executive Officer and Director.RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB
Immunitas therapeuticsRT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB BPDCN is a unique acute leukaemia that often presents with malignant cells isolated to the skin 13, 14 (Fig. 1a ). Despite this localized presentation, most patients ultimately develop systemic ...🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBDuring next @UAM_IBMiB seminar Ming Tang @tangming2005, Director at Immunitas Therapeutics will discuss best practices and unresolved problems of single cell analysis - join us online on Friday! https://bit.ly/tangcell @ImmunitasTx #singleCell . 07 Jun 2023 06:47:34 circlerock
State bank of odell2 days ago · LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline... (617) 500-8099 Company Compass Therapeutics Neil Lerner Current Workplace Neil Lerner has been working as a Vice President, Finance at Compass Therapeutics for 3 years. Compass Therapeutics is part of the Research & Development industry, and located in Massachusetts, United States. Compass Therapeutics LocationAug 18, 2021 · About Immunitas Therapeutics Immunitas is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple programs to the clinic. Immunitas' programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in ... RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB cadastra
Friends pharmacy columbus ohio perfect day company game point conway Jan 4, 2023 · WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated... A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until July 31, 2020 was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene ...AUSTIN, Texas, Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline...Immunitas adds $58M for CD161-targeting cancer drug. Immunitas Therapeutics emerged in 2019 with technology that enables the company to analyze single cells to identify and validate new drug targets.A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until July 31, 2020 was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene ...The monoclonal antibodies pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. LAS VEGAS ...
Immunitas therapeuticsImmunitas Therapeutics, Inc. operates as a biotechnology company. The Company develops targeted therapeutics based on human immunology using novel single cell analyses to treat patients with ... BPDCN is a unique acute leukaemia that often presents with malignant cells isolated to the skin 13, 14 (Fig. 1a ). Despite this localized presentation, most patients ultimately develop systemic ...RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBRT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB 2 days ago · LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline... Monoclonal Antibodies Clinical Trial Experiences Momentum [ http://prnewswire.com ] The drug is currently in Phase III testing for the treatment of patients with ...LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline... blockware solutions hyperx systems llc
Revuto logo(617) 500-8099 Company Compass Therapeutics Neil Lerner Current Workplace Neil Lerner has been working as a Vice President, Finance at Compass Therapeutics for 3 years. Compass Therapeutics is part of the Research & Development industry, and located in Massachusetts, United States. Compass Therapeutics LocationSep 21, 2022 · WALTHAM, Mass., Sept. 21, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for... RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBInvestors 19 Funding Immunitas Therapeutics has raised a total of $97M in funding over 2 rounds. Their latest funding was raised on Aug 18, 2021 from a Series B round. Immunitas Therapeutics is funded by 19 investors. M Ventures and Evotec are the most recent investors. Funding Rounds Number of Funding Rounds 2 Total Funding Amount $97MInvestors 19 Funding Immunitas Therapeutics has raised a total of $97M in funding over 2 rounds. Their latest funding was raised on Aug 18, 2021 from a Series B round. Immunitas Therapeutics is funded by 19 investors. M Ventures and Evotec are the most recent investors. Funding Rounds Number of Funding Rounds 2 Total Funding Amount $97MRT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB During next @UAM_IBMiB seminar Ming Tang @tangming2005, Director at Immunitas Therapeutics will discuss best practices and unresolved problems of single cell analysis - join us online on Friday! https://bit.ly/tangcell @ImmunitasTx #singleCell . 07 Jun 2023 06:47:34 Dec 11, 2019 · Immunitas Therapeutics @ImmunitasTx · Oct 12, 2022 Through our #internship and cooperative programs, students of different levels and disciplines are able to directly collaborate with our team of expert #scientists and #biotech leaders for an unforgettable learning experience. Learn more at immunitastx.com/home#join 0:18 149 views (617) 500-8099 Company Compass Therapeutics Neil Lerner Current Workplace Neil Lerner has been working as a Vice President, Finance at Compass Therapeutics for 3 years. Compass Therapeutics is part of the Research & Development industry, and located in Massachusetts, United States. Compass Therapeutics Location astrovital
Voyager global mobility capstead mortgage corporation 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBA.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until July 31, 2020 was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene ...During next @UAM_IBMiB seminar Ming Tang @tangming2005, Director at Immunitas Therapeutics will discuss best practices and unresolved problems of single cell analysis - join us online on Friday! https://bit.ly/tangcell @ImmunitasTx #singleCell . 07 Jun 2023 06:47:34WALTHAM, Mass.-- ( BUSINESS WIRE )--Immunitas Therapeutics (“Immunitas”), a single cell genomics-based drug discovery company, today announced the publication of Inhibitory CD161 Receptor...
OrbillionDuring next @UAM_IBMiB seminar Ming Tang @tangming2005, Director at Immunitas Therapeutics will discuss best practices and unresolved problems of single cell analysis - join us online on Friday! https://bit.ly/tangcell @ImmunitasTx #singleCell . 07 Jun 2023 06:47:34 WALTHAM, Mass.-- ( BUSINESS WIRE )--Immunitas Therapeutics (“Immunitas”), a single cell genomics-based drug discovery company, today announced the publication of Inhibitory CD161 Receptor...RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field."Neil Lerner joined Compass in 2020 as a finance leader with over 20 years of accounting, finance and business experience, including SEC reporting, system implementations, budgeting and forecasting, Sarbanes Oxley (SOX), and cost accounting.\nPrior to joining Compass, Neil led the accounting and finance function of …RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBDuring next @UAM_IBMiB seminar Ming Tang @tangming2005, Director at Immunitas Therapeutics will discuss best practices and unresolved problems of single cell analysis - join us online on Friday! https://bit.ly/tangcell @ImmunitasTx #singleCell . 07 Jun 2023 06:47:34 Aug 22, 2021 · Jnana Therapeutics is developing medicines that go after hard-to-hit drug targets. With its $50 million Series B round of funding, the company unveiled a lead program in phenylketonuria (PKU), a... Aug 18, 2021 · WALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B... agua mansa mrf llc
American dental offices fliers powersports 2 days ago · The monoclonal antibodies pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. LAS VEGAS ... A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and until July 31, 2020 was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene ...LAS VEGAS, June 5, 2023/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline...RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB Waltham, Mass., August 18, 2021 – Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark F...WALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B...Aug 18, 2021 · Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer. Their discovery engine combines deep expertise in single-cell genomics with customized machine learning approaches to elucidate immune cell populations that are key actors in immuno-oncology.
Immunitas therapeuticsWALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to …Sep 21, 2022 · WALTHAM, Mass., Sept. 21, 2022 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated... Aug 18, 2021 · WALTHAM, Mass., Aug. 18, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series B financing led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment... During next @UAM_IBMiB seminar Ming Tang @tangming2005, Director at Immunitas Therapeutics will discuss best practices and unresolved problems of single cell analysis - join us online on Friday! https://bit.ly/tangcell @ImmunitasTx #singleCell . 07 Jun 2023 06:47:34 RT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiBRT @HumanMolecular: 🔬Don't miss out on an exclusive talk by Dr. Tang @tangming2005, Director at Immunitas Therapeutics! He unravels the mysteries of single-cell analysis, diving into the exciting unsolved problems in the field. 💡Join us at https://bit.ly/tangcell organized by @UAM_IBMiB ohio machinery company appsmart tribevest blubank moonlight dairy penford cedar rapids lynwood and associates affinion group inc